Eiger Biopharmaceuticals Inc (EIGRQ)

Market Cap	2.55M
Revenue (ttm)	15.77M
Net Income (ttm)	-74.96M
Shares Out	1.48M
EPS (ttm)	-50.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,020
Open	4.000
Previous Close	2.390
Day's Range	2.390 - 4.160
52-Week Range	1.610 - 4.160
Beta	1.85
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About EIGRQ

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 56
• Stock Exchange: OTCMKTS
• Ticker Symbol: EIGRQ

Financial Performance

In 2023, EIGRQ's revenue was $15.77 million, an increase of 16.98% compared to the previous year's $13.48 million. Losses were -$74.96 million, -22.54% less than in 2022.

Financial numbers in USD